UroGen Q2 FY26 net loss narrows to $14.4 million; revenue rises to $72.5 million - URGN News | RalliesUroGen Q2 FY26 net loss narrows to $14.4 million; revenue rises to $72.5 million
U
URGN• Q2 FY26 results
- UroGen posted Q2 2026 revenue of $72.5 million, up from $24.2 million a year earlier; net loss narrowed to $14.4 million.
- ZUSDURI revenue climbed 73% quarter-over-quarter to $50.4 million; operating income was $111,000.
- SG&A expenses rose to $48.4 million, reflecting ZUSDURI commercial activities; R&D expenses eased to $17.3 million.
- Cash, cash equivalents and marketable securities totaled $108 million; full-year operating expense guidance increased to $260 million-$270 million.
- Management cited a new U.S. patent allowance expected to protect ZUSDURI and UGN-103 into July 2044; UGN-103 remains on track for an NDA in Q3 2026.
BKNG
•
